Skip to main content
. 2024 May 6;11:1385238. doi: 10.3389/fmolb.2024.1385238

FIGURE 3.

FIGURE 3

Circulating tumor DNA/cfDNA have multiple features and modifications, which are explored and tested for clinical decisions about risk, relapse, survival, and therapy responses. cfDNA or ctDNA is useful for dynamic monitoring, therapy responses, and risk assessment of relapse. Possibilities for the risk of assessment of CTCs for prognostic and other clinical applications.